Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Brighton Pier Group shares plummet on plans to go private

(Sharecast News) - Brighton Pier Group has announced plans to delist from AIM, saying it is in the best interest of the company and its shareholders, causing shares to plummet on Wednesday. The leisure and entertainment business said "persistent challenging trading conditions" over the past several years have been compounded by the looming increases to employer contributions to national insurance and hikes in the minimum wage, as well as high interest rates and surging energy costs.

While the company has attempted to save money, dispose of underperforming assets and limit its investment, continued challenges led to a review of its strategic options.

BPG said that the costs and regulatory burden of being listed on AIM, along with a lack of liquidity in its shares and market volatility, have led to its decision to delist. Meanwhile, being a private company should give it more flexibility to "take and implement decisions more quickly".

BPG, which will be seeking shareholder approval for the proposed cancellation of shares, said shareholders are "not required, if they do not wish, to dispose of their ordinary shares in any manner".

However, that didn't stop the stock from plunging 56% to 7.56p by 0854 GMT.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.